STERIS' (STE) Healthcare business and strong rebound prospects of the AST segment appear encouraging. However, macroeconomic concerns remain a challenge.

STERIS' (STE) AST successfully offers a wide range of sterilization modalities through a worldwide network of more than 50 contract sterilization and laboratory facilities.

Explore how Steris' (STE) revenue from international markets is changing and the resulting impact on Wall Street's predictions and the stock's prospects.

STERIS plc (NYSE:STE ) Q4 2024 Earnings Conference Call May 9, 2024 9:00 AM ET Company Participants Julie Winter - VP, IR Mike Tokich - SVP and CFO Dan Carestio - President and CEO Conference Call ...

STERIS' (STE) fourth-quarter performance in AST is dented by a decline in capital equipment revenues. The contraction of margins is concerning.

While the top- and bottom-line numbers for Steris (STE) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare ...

Steris (STE) came out with quarterly earnings of $2.41 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $2.30 per share a year ago.

Get a deeper insight into the potential performance of Steris (STE) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for som...

STERIS' (STE) strong prospects in the healthcare and pharmaceutical industries bode well for investors.

STERIS (STE) is expected to have witnessed the normalization of the Healthcare backlog, as the company is currently able to ship at a faster pace than the receipt of new orders.

The heavy selling pressure might have exhausted for Steris (STE) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts i...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

STERIS' (STE) fiscal 2024 third-quarter results demonstrate the remarkable performance of the Healthcare segment.

The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street esti...